Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model
暂无分享,去创建一个
Keith A. Vossel | K. Vossel | L. Mucke | J. Cirrito | J. Palop | N. Devidze | Kaitlyn Ho | Pascal E. Sanchez | Lennart Mucke | L. Verret | Gui-Qiu Yu | Kaitlyn Ho | John R. Cirrito | Laure Verret | Anna G. Orr | Nino Devidze | Jorge J. Palop | Lei Zhu | Gui-qiu Yu | Lei Zhu | P. Sanchez
[1] Amy L. Shelton,et al. Reduction of Hippocampal Hyperactivity Improves Cognition in Amnestic Mild Cognitive Impairment , 2012, Neuron.
[2] Edward O. Mann,et al. Inhibitory Interneuron Deficit Links Altered Network Activity and Cognitive Dysfunction in Alzheimer Model , 2012, Cell.
[3] L. Mucke,et al. Alzheimer Mechanisms and Therapeutic Strategies , 2012, Cell.
[4] Kelly O'Keefe,et al. Hippocampal Hyperactivation Associated with Cortical Thinning in Alzheimer's Disease Signature Regions in Non-Demented Elderly Adults , 2011, The Journal of Neuroscience.
[5] D. Bredesen,et al. Abnormal neuronal networks and seizure susceptibility in mice overexpressing the APP intracellular domain , 2011, Neurobiology of Aging.
[6] D. Holtzman,et al. Opposing Synaptic Regulation of Amyloid-β Metabolism by NMDA Receptors In Vivo , 2011, The Journal of Neuroscience.
[7] S. Rothman,et al. A new mechanism for antiepileptic drug action: vesicular entry may mediate the effects of levetiracetam. , 2011, Journal of neurophysiology.
[8] Shaomin Li,et al. Soluble Aβ Oligomers Inhibit Long-Term Potentiation through a Mechanism Involving Excessive Activation of Extrasynaptic NR2B-Containing NMDA Receptors , 2011, The Journal of Neuroscience.
[9] Jee Hoon Roh,et al. Neuronal activity regulates the regional vulnerability to amyloid-β deposition , 2011, Nature Neuroscience.
[10] K. Lyseng-Williamson. Levetiracetam: a review of its use in epilepsy. , 2011, Drugs.
[11] H. Tanila,et al. Spontaneous epileptiform discharges in a mouse model of Alzheimer's disease are suppressed by antiepileptic drugs that block sodium channels , 2011, Epilepsy Research.
[12] Todd E. Golde,et al. Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift , 2011, Neuron.
[13] L. Mucke,et al. Amyloid-β/Fyn–Induced Synaptic, Network, and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer's Disease , 2011, The Journal of Neuroscience.
[14] Julie Harris,et al. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model , 2011, Nature.
[15] Erik D Roberson,et al. Quantifying biomarkers of cognitive dysfunction and neuronal network hyperexcitability in mouse models of Alzheimer's disease: depletion of calcium-dependent proteins and inhibitory hippocampal remodeling. , 2011, Methods in molecular biology.
[16] Julie A. Harris,et al. Transsynaptic Progression of Amyloid-β-Induced Neuronal Dysfunction within the Entorhinal-Hippocampal Network , 2010, Neuron.
[17] S. Kar,et al. β-Amyloid-related peptides potentiate K+-evoked glutamate release from adult rat hippocampal slices , 2010, Neurobiology of Aging.
[18] L. Mucke,et al. Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks , 2010, Nature Neuroscience.
[19] Todd E. Golde,et al. Targeting Aβ and tau in Alzheimer's disease, an early interim report , 2010, Experimental Neurology.
[20] E. Cumbo,et al. Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer’s disease , 2010, Epilepsy & Behavior.
[21] E. Aronica,et al. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures , 2010, Nature Medicine.
[22] Michela Gallagher,et al. Treatment Strategies Targeting Excess Hippocampal Activity Benefit Aged Rats with Cognitive Impairment , 2010, Neuropsychopharmacology.
[23] G. D. Paolo,et al. Faculty Opinions recommendation of Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses. , 2010 .
[24] I. Bezprozvanny,et al. The dysregulation of intracellular calcium in Alzheimer disease. , 2010, Cell calcium.
[25] R. Scott,et al. Hippocampal interictal spikes disrupt cognition in rats , 2010, Annals of neurology.
[26] Julie A. Harris,et al. Many Neuronal and Behavioral Impairments in Transgenic Mouse Models of Alzheimer's Disease Are Independent of Caspase Cleavage of the Amyloid Precursor Protein , 2010, The Journal of Neuroscience.
[27] M. Bialer,et al. Key factors in the discovery and development of new antiepileptic drugs , 2010, Nature Reviews Drug Discovery.
[28] Keith A. Johnson,et al. Functional Alterations in Memory Networks in Early Alzheimer’s Disease , 2010, NeuroMolecular Medicine.
[29] S. Rothman,et al. Levetiracetam has a time- and stimulation-dependent effect on synaptic transmission , 2009, Seizure.
[30] Keith A. Johnson,et al. Amyloid Deposition Is Associated with Impaired Default Network Function in Older Persons without Dementia , 2009, Neuron.
[31] Shaomin Li,et al. Soluble Oligomers of Amyloid β Protein Facilitate Hippocampal Long-Term Depression by Disrupting Neuronal Glutamate Uptake , 2009, Neuron.
[32] L. Mucke,et al. Epilepsy and cognitive impairments in Alzheimer disease. , 2009, Archives of neurology.
[33] Sylvain Rheims,et al. Amyloid β-Induced Neuronal Hyperexcitability Triggers Progressive Epilepsy , 2009, The Journal of Neuroscience.
[34] I. Bezprozvanny. Calcium signaling and neurodegenerative diseases. , 2009, Trends in molecular medicine.
[35] T. Südhof,et al. SV2 Renders Primed Synaptic Vesicles Competent for Ca2+-Induced Exocytosis , 2009, The Journal of Neuroscience.
[36] F. H. Lopes da Silva,et al. Development of tolerance to levetiracetam in rats with chronic epilepsy , 2008, Epilepsia.
[37] Guojun Bu,et al. Endocytosis Is Required for Synaptic Activity-Dependent Release of Amyloid-β In Vivo , 2008, Neuron.
[38] Anatol C. Kreitzer,et al. Aberrant Excitatory Neuronal Activity and Compensatory Remodeling of Inhibitory Hippocampal Circuits in Mouse Models of Alzheimer's Disease , 2007, Neuron.
[39] L. Mucke,et al. Accelerating Amyloid-β Fibrillization Reduces Oligomer Levels and Functional Deficits in Alzheimer Disease Mouse Models* , 2007, Journal of Biological Chemistry.
[40] L. Willmore,et al. Effect of levetiracetam on molecular regulation of hippocampal glutamate and GABA transporters in rats with chronic seizures induced by amygdalar FeCl3 injection , 2007, Brain Research.
[41] L. Mucke,et al. Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.
[42] R. Raedt,et al. Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug. , 2007, CNS drug reviews.
[43] R. Raedt,et al. Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data. , 2007, CNS drug reviews.
[44] L. Mucke,et al. A network dysfunction perspective on neurodegenerative diseases , 2006, Nature.
[45] Vince D. Calhoun,et al. Alterations in Memory Networks in Mild Cognitive Impairment and Alzheimer's Disease: An Independent Component Analysis , 2006, The Journal of Neuroscience.
[46] Dieter Schmidt,et al. Experimental and Clinical Evidence for Loss of Effect (Tolerance) during Prolonged Treatment with Antiepileptic Drugs , 2006, Epilepsia.
[47] Jean Gotman,et al. EEG–fMRI of epileptic spikes: Concordance with EEG source localization and intracranial EEG , 2006, NeuroImage.
[48] J. Gotman,et al. Temporal and Extratemporal BOLD Responses to Temporal Lobe Interictal Spikes , 2006, Epilepsia.
[49] N. S. Austin,et al. Synaptic Vesicle Protein 2 Enhances Release Probability at Quiescent Synapses , 2006, The Journal of Neuroscience.
[50] Steven Mennerick,et al. Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo , 2005, Neuron.
[51] L. Mucke,et al. Fyn Kinase Induces Synaptic and Cognitive Impairments in a Transgenic Mouse Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.
[52] M. Albert,et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD , 2005, Neurology.
[53] Xiao-Min Wang,et al. Effects of distinct classes of N-methyl-d-aspartate receptor antagonists on seizures, axonal sprouting and neuronal loss in vitro: suppression by NR2B-selective antagonists , 2004, Neuropharmacology.
[54] K. Nocka,et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[55] C. Binnie,et al. Cognitive impairment during epileptiform discharges: is it ever justifiable to treat the EEG? , 2003, The Lancet Neurology.
[56] D. Holtzman,et al. In Vivo Assessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-β Metabolism and Half-Life , 2003, The Journal of Neuroscience.
[57] Jacob Raber,et al. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[58] R. Malinow,et al. APP Processing and Synaptic Function , 2003, Neuron.
[59] E. Ben-Menachem,et al. Levetiracetam reduces caffeine-induced Ca2+ transients and epileptiform potentials in hippocampal neurons , 2003, Neuroreport.
[60] Josemir W Sander,et al. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy , 2003, Epilepsy Research.
[61] M. Mendez,et al. Seizures in Elderly Patients with Dementia , 2003, Drugs & aging.
[62] W. Löscher,et al. Effects of the Novel Antiepileptic Drug Levetiracetam on Spontaneous Recurrent Seizures in the Rat Pilocarpine Model of Temporal Lobe Epilepsy , 2002, Epilepsia.
[63] N. Danbolt. Glutamate uptake , 2001, Progress in Neurobiology.
[64] Patrick Kwan,et al. Neuropsychological effects of epilepsy and antiepileptic drugs , 2001, The Lancet.
[65] W. Löscher,et al. Development of Tolerance During Chronic Treatment of Kindled Rats With the Novel Antiepileptic Drug Levetiracetam , 2000, Epilepsia.
[66] Kang Hu,et al. High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.
[67] M R Symms,et al. EEG-triggered functional MRI of interictal epileptiform activity in patients with partial seizures. , 1999, Brain : a journal of neurology.
[68] R. Motter,et al. Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease , 1997 .
[69] L. Mucke,et al. Levels and Alternative Splicing of Amyloid β Protein Precursor (APP) Transcripts in Brains of APP Transgenic Mice and Humans with Alzheimer's Disease (*) , 1995, The Journal of Biological Chemistry.